A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

StatusRecruiting
PhasePhase 3
SponsorCelgene
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 15 wordsv17
  2. Site contacts updated at 7 of 160 sitesv16
  3. Eligibility criteria shortened, about 51 words
    • Study title expanded, about 11 words
    v15
  4. Study sites: 159 to 160v14
  5. Study sites revised (159)v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 156 to 159v12
  2. Study sites: 154 to 156v11
  3. Study sites revised (154)v10
  4. Study sites: 151 to 154v9
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 148 to 151
    • Start date changed from estimate of Jul 8, 2025 to Jul 28, 2025
    v8
  6. Study sites: 146 to 148v7
  7. Study sites: 145 to 146v6
  8. Primary completion date: Jul 31, 2030 to Apr 24, 2028
    • Study sites: 143 to 145
    v5
  9. Study sites: 117 to 143v4
  10. Study sites: 113 to 117v3
  11. Study sites: 109 to 113v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Trial Details
NCT Number NCT06911502
Lead Sponsor Celgene
Conditions
(from sponsor)		 Follicular Lymphoma
Related terms Lymphoma, Follicular
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov